Biotech News
Timberlyne Therapeutics Secures $180M Series A to Best-in-Class Anti-CD38 Monoclonal Antibody
Timberlyne Therapeutics, a clinical-stage biopharmaceutical company, has closed a $180 million Series A funding round to advance its monoclonal antibody, CM313, targeting autoimmune diseases with unmet medical needs. The round was led by Abingworth, Bain Capital Life Sciences, and Venrock
17 January 2025